Vytrus Biotech (XMAD:VYT) Total Liabilities: €4.36 Mil (As of Dec. 2025)


XMAD:VYT Vytrus Biotech SA XMAD:VYT
69 GF Score
Price €17.40
GF Value €5.54
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Total Liabilities?

Vytrus Biotech XMAD:VYT -0.57% 69 Total Liabilities is €4.36 Mil as of Dec. 2025. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.54 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Vytrus Biotech's Total Liabilities for the quarter that ended in Dec. 2025 was €4.36 Mil.

Vytrus Biotech's quarterly Total Liabilities increased from Dec. 2024 (€3.84 Mil) to Jun. 2025 (€4.27 Mil) and increased from Jun. 2025 (€4.27 Mil) to Dec. 2025 (€4.36 Mil).

Vytrus Biotech's annual Total Liabilities declined from Dec. 2023 (€4.02 Mil) to Dec. 2024 (€3.84 Mil) but then increased from Dec. 2024 (€3.84 Mil) to Dec. 2025 (€4.36 Mil).

Vytrus Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Total Liabilities Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 2.93 3.25 4.02 3.84 4.36

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.02 3.84 3.84 4.27 4.36
XMAD:VYT
69GF Score
Vytrus Biotech SA XMAD:VYT
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vytrus Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.777+(1.543+1.035
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.36

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=14.663-10.308
=4.36

Vytrus Biotech's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.777+(1.543+1.035
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=4.36

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=14.663-10.308
=4.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €4.36 Mil mean?
Vytrus Biotech (XMAD:VYT) has a Total Liabilities of €4.36 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vytrus Biotech and its competitors.
Is Vytrus Biotech's Total Liabilities too high?
Vytrus Biotech's current Total Liabilities is €4.36 Mil. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Total Liabilities compare to VRTX and REGN?
Vytrus Biotech's Total Liabilities of €4.36 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vytrus Biotech and its competitors. Vytrus Biotech's current Total Liabilities is €4.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.54, compared to a current price of €17.40 — trading 214.1% above its estimated fair value. The current Total Liabilities is €4.36 Mil. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Total Liabilities is €4.36 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €17.40 is trading 214.1% above its estimated GF Value™ of €5.54. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for XMAD:VYT:

  • Total Liabilities: €4.36 Mil
  • GF Value™: €5.54 vs. price of €17.40 (214.1% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges V5P:Germany
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score

Get the complete analysis for XMAD:VYT

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.40
Price
€5.54
GF Value